Much of US pharma keeping promise on price hike caps, says report

As part of a growing tradition, the new year coincides with a hike in US pharmaceutical prices, with more than 30 drugs seeing an increase in price.

However, after receiving continued criticism from both the public and politicians, it appears that the industry is sticking within a 10% self-imposed price-hike limit, observes data and analytics company GlobalData.

This 10% cap appears to have become a social contract in the pharma industry since 2016, when Ireland-incorporated Allergan (NYSE: AGN) chief executive Brent Saunders pledged to police pricing, stating that Allergan would limit itself to one price increase per year and would only increase prices by single-digit percentages.